Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin
January 27, 2015
- Xtandi Significantly Prolongs PFS in PII Study in Europe, US: Astellas
January 27, 2015
- Senshio Approved in Europe for Treatment of Symptomatic Vulvar, Vaginal Atrophy: Shionogi
January 26, 2015
- Takara Bio to Initiate Clinical Trial for Anticancer Agent HF10 in Japan
January 26, 2015
- US FDA Advisory Committee Recommends Approval of Astellas’s Azole Antifungal Agent
January 26, 2015
- Nihon Chouzai Confident of Continuing Early Price Settlements
January 23, 2015
- Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
- Lifestyle Disease-Related Medical Spending Must Be Pruned: Nobelpharma Pres.
January 22, 2015
- Medical System Network President Calls for Scrapping Fee Cut Rule
January 21, 2015
- Sakura Finetek Japan to Participate in Cervical Cancer Screening Project in Kazakhstan
January 21, 2015
- Meiji Seika Pharma Licenses Darinaparsin from Solasia Pharma in Japan
January 20, 2015
- Sanofi Launches Allegra Dry Syrup for Pediatric Patients Aged 6 Months and Older
January 20, 2015
- Pharma Bigwigs Stress Importance of Early Patent Strategies
January 19, 2015
- Foreign-Affiliated Pharmas Looking to Make “Sure Investments” to Avoid Risk of Discontinued Development: PhRMA Official
January 19, 2015
- Mr Plata Named as AbbVie G.K.’s New President
January 19, 2015
- Belsomra Most Heavily Pitched Drug in November: Anterio Ranking
January 16, 2015
- Toyama Chemical Commences PII Study for Solithromycin in Japan
January 16, 2015
- Sumitomo Dainippon Files Latuda Patent Infringement Lawsuits in US against 3 Pharmas
January 16, 2015
- Otsuka Completes Acquisition of Avanir for US$3.56 Billion
January 15, 2015
- Lantus Biosimilar Approved: Eli Lilly Japan, NBI
January 15, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…